Investigational Drug Information for Fasudil
✉ Email this page to a colleague
What is the development status for investigational drug Fasudil?
Fasudil is an investigational drug.
There have been 14 clinical trials for Fasudil.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2019.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Shahid Beheshti University of Medical Sciences, Woolsey Pharmaceuticals, and Brigham and Women's Hospital.
There are five hundred and fifty-three US patents protecting this investigational drug and ten international patents.
Summary for Fasudil
| US Patents | 553 |
| International Patents | 10,864 |
| US Patent Applications | 3,572 |
| WIPO Patent Applications | 1,842 |
| Japanese Patent Applications | 908 |
| Clinical Trial Progress | Phase 3 (2019-07-01) |
| Vendors | 66 |
Recent Clinical Trials for Fasudil
| Title | Sponsor | Phase |
|---|---|---|
| Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis | Woolsey Pharmaceuticals | Phase 2 |
| Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 | Woolsey Pharmaceuticals | Phase 2 |
| Fasudil fOr redUcing elopemeNt and Spatial Disorientation | Woolsey Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Fasudil
Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil
US Patents for Fasudil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fasudil | See Plans and Pricing | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | Minimal volume reprogramming of mononuclear cells | Fate Therapeutics, Inc. (San Diego, CA) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | SC-.beta. cells and compositions and methods for generating the same | President and Fellows of Harvard College (Boston, MA) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | Six-membered C--N-bonded aryl sulphide and aryl sulphoxide derivatives as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases | International Stem Cell Corporation (Carlsbad, CA) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | sGC stimulators | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Fasudil | See Plans and Pricing | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fasudil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fasudil | European Patent Office | EP2981556 | 2033-04-02 | See Plans and Pricing |
| Fasudil | World Intellectual Property Organization (WIPO) | WO2014165513 | 2033-04-02 | See Plans and Pricing |
| Fasudil | Australia | AU2015286634 | 2034-07-11 | See Plans and Pricing |
| Fasudil | Brazil | BR112017000398 | 2034-07-11 | See Plans and Pricing |
| Fasudil | China | CN106659720 | 2034-07-11 | See Plans and Pricing |
| Fasudil | European Patent Office | EP3177291 | 2034-07-11 | See Plans and Pricing |
| Fasudil | Japan | JP2017519802 | 2034-07-11 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
